The move from injections to tablets is accelerating the growth of the obesity drug market.
Daily GLP-1 pills are easier to take, cheaper to store and appeal to people who avoid needles.
Analysts expect the sector to reach about $200bn by the early 2030s.
Novo Nordisk launched the first oral Wegovy for weight loss in the US in December.
Prescriptions climbed rapidly, drawing both new patients and people switching from jabs.
Users report more consistent appetite control, although they must remember a daily dose.
Eli Lilly is preparing a rival pill that may be easier to absorb and take.
Competition is intensifying as more companies develop oral and combination therapies.
Injections still produce greater weight loss and will suit people with severe obesity.
Pills are expected to attract a broader group who are overweight or mildly obese.
Lower prices and expanding insurance coverage should further boost demand.
Rising global obesity rates continue to drive the market.
Researchers say most eligible patients still receive no treatment.
The arrival of effective tablets marks a pivotal new phase for weight-loss drugs.
